A phase I study to evaluate the pharmacological effects of RQ-00000004 using a biomarker testing as well as its safety, tolerability and pharmacokinetic profiles in Japanese subjects
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2016
Price : $35 *
At a glance
- Drugs Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2016 Status changed from recruiting to completed, as per ReQualia media release.
- 25 Jun 2015 According to a RaQualia media release, the company has finished administration in this study and preparing for a clinical study report.
- 26 Jul 2014 New trial record